Neurogene Inc (NGNE)

$31.54 +0.65 (2.10%)
Market Cap 482.38M
Revenue (ttm) 0.00
Net Income (ttm) -90.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 103,400
Avg Vol 162,918
Day's Range N/A - N/A
Shares Out 15.62M
Stochastic %K 77%
Beta 1.69
Analysts Strong Sell
Price Target $76.43

Company Profile

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC...

Industry: Biotechnology
Sector: Healthcare
Phone: 855 508 3568
Address:
535 W 24th Street, 5th Floor, New York, United States
d_risk
d_risk May. 12 at 8:33 PM
$NGNE - Neurogene Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +264.9% above peer average (42,757 vs 11,717 across 653 peers). NGNE’s 10‑Q adds sharper warnings on NGN‑401’s safety after a fatal AAV event, expanded clinical/regulatory uncertainty (incl. foreign trials, expedited and orphan/RPD designations offering no guarantees), heavier financing and single‑asset dependence, concentration and weather risk at its Houston plant, greater IP/licensing and litigation exposure, tighter global pricing/reimbursement and China/AML compliance risks, CVR/merger overhead, and newly flagged internal‑control weaknesses as a recent SPAC‑style reverse‑merger public company. 🟢 Added 🟠 Removed https://d-risk.ai/NGNE/10-Q/2026-05-12
0 · Reply
Buerll
Buerll May. 12 at 12:24 PM
$NGNE https://www.stocktitan.net/news/NGNE/neurogene-highlights-data-at-asgct-meeting-supporting-therapeutic-ek25bd65edsu.html
0 · Reply
King_of_Bio
King_of_Bio May. 6 at 7:23 PM
$NGNE Looking famn good
0 · Reply
lukasgx
lukasgx May. 6 at 2:42 PM
$NGNE hitting new high in few weeks
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 29 at 11:20 PM
$NGNE Current Stock Price: $26.44 Contracts to trade: $25.0 NGNE May 15 2026 Call Entry: $1.50 Exit: $2.00 ROI: 34% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Buerll
Buerll Apr. 28 at 1:22 PM
$NGNE https://m.in.investing.com/news/stock-market-news/guggenheim-reiterates-neurogene-stock-rating-with-69-target-93CH-5362097?ampMode=1
0 · Reply
laaarsas
laaarsas Apr. 27 at 6:20 PM
$NGNE So what data is expected here in the summer?
0 · Reply
lukasgx
lukasgx Apr. 27 at 3:29 PM
$NGNE climbing over 40+++
1 · Reply
focafoca99
focafoca99 Apr. 20 at 1:39 PM
$NGNE appointed Christy Shafer as chief commercial officer and added Christine Mikail to its board.
0 · Reply
Gogobisous
Gogobisous Apr. 20 at 12:21 PM
$NGNE looks like they might be gearing up for not only for commercialization but a strategic transaction. https://ir.neurogene.com/news-releases/news-release-details/neurogene-appoints-christy-shafer-chief-commercial-officer-and
0 · Reply
Latest News on NGNE
Neurogene reports Q1 EPS ($1.39), consensus ($1.27)

2026-05-12T21:23:46.000Z - 15 hours ago

Neurogene reports Q1 EPS ($1.39), consensus ($1.27)

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

May 12, 2026, 4:05 PM EDT - 17 hours ago

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

May 12, 2026, 6:00 AM EDT - 1 day ago

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2026, 4:01 PM EDT - 6 days ago

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene to present on ICV delivery in CNS-targeted gene therapy

2026-04-28T12:07:09.000Z - 15 days ago

Neurogene to present on ICV delivery in CNS-targeted gene therapy

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

Apr 28, 2026, 7:30 AM EDT - 15 days ago

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

Neurogene initiated with a Buy at Guggenheim

2026-04-28T10:10:26.000Z - 15 days ago

Neurogene initiated with a Buy at Guggenheim

Neurogene appoints Christy Shafer as CCO

2026-04-20T11:47:51.000Z - 23 days ago

Neurogene appoints Christy Shafer as CCO

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

Apr 20, 2026, 7:30 AM EDT - 23 days ago

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

Neurogene price target lowered to $180 from $200 at Canaccord

2026-04-06T11:00:08.000Z - 5 weeks ago

Neurogene price target lowered to $180 from $200 at Canaccord

Neurogene reports FY25 EPS ($4.24) vs ($4.28) last year

2026-03-24T11:35:35.000Z - 7 weeks ago

Neurogene reports FY25 EPS ($4.24) vs ($4.28) last year

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

Mar 24, 2026, 7:30 AM EDT - 7 weeks ago

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

Neurogene Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 9:00 AM EDT - 2 months ago

Neurogene Transcript: Stifel 2026 Virtual CNS Forum

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 7:30 AM EDT - 2 months ago

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

Neurogene Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:40 PM EDT - 2 months ago

Neurogene Transcript: Leerink Global Healthcare Conference 2026

Neurogene Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 2 months ago

Neurogene Transcript: TD Cowen 46th Annual Health Care Conference

Canaccord starts Neurogene with Buy rating, $200 price target

2026-02-27T11:46:23.000Z - 2 months ago

Canaccord starts Neurogene with Buy rating, $200 price target

Neurogene initiated with a Buy at Canaccord

2026-02-27T10:50:55.000Z - 2 months ago

Neurogene initiated with a Buy at Canaccord

Neurogene jumps 36% to $26.71 after Canaccord puts $200 target on shares

2026-02-27T10:50:14.000Z - 2 months ago

Neurogene jumps 36% to $26.71 after Canaccord puts $200 target on shares

Neurogene announces Treakthrough Therapy Designation for NGN-401

2026-02-26T21:12:03.000Z - 2 months ago

Neurogene announces Treakthrough Therapy Designation for NGN-401

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

Feb 26, 2026, 4:01 PM EST - 2 months ago

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

Neurogene Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 9:00 AM EST - 3 months ago

Neurogene Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Neurogene to Participate in Upcoming Investor Conferences

Feb 5, 2026, 7:30 AM EST - 3 months ago

Neurogene to Participate in Upcoming Investor Conferences

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 4, 2026, 4:01 PM EST - 3 months ago

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neurogene initiated with an Outperform at LifeSci Capital

2026-01-26T12:55:28.000Z - 3 months ago

Neurogene initiated with an Outperform at LifeSci Capital

Neurogene Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 10:30 AM EST - 4 months ago

Neurogene Transcript: 44th Annual J.P. Morgan Healthcare Conference

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

Jan 12, 2026, 7:00 AM EST - 4 months ago

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:30 AM EST - 4 months ago

Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Neurogene reports Q3 EPS (99c) vs. ($1.19) last year

2025-11-13T22:15:33.000Z - 6 months ago

Neurogene reports Q3 EPS (99c) vs. ($1.19) last year

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

Nov 13, 2025, 5:10 PM EST - 6 months ago

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

Neurogene price target raised to $70 from $65 at H.C. Wainwright

2025-11-13T11:31:17.000Z - 6 months ago

Neurogene price target raised to $70 from $65 at H.C. Wainwright

Neurogene Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 4:40 PM EST - 6 months ago

Neurogene Transcript: Stifel 2025 Healthcare Conference

Neurogene reports interim data in Pediatric Cohort from NGN-401 trial

2025-11-12T21:11:21.000Z - 6 months ago

Neurogene reports interim data in Pediatric Cohort from NGN-401 trial

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

Nov 12, 2025, 4:01 PM EST - 6 months ago

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

Neurogene doses first patient in NGN-401 clinical trial

2025-11-06T14:47:47.000Z - 6 months ago

Neurogene doses first patient in NGN-401 clinical trial

Neurogene Announces First Participant Dosed in Emboldenâ„¢ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Nov 6, 2025, 7:30 AM EST - 6 months ago

Neurogene Announces First Participant Dosed in Emboldenâ„¢ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Neurogene Transcript: H. C. Wainwright Genetic Medicines Virtual Conference

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Emboldenâ„¢ Registrational Trial in Q4 2025

Oct 9, 2025, 7:00 AM EDT - 7 months ago

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Emboldenâ„¢ Registrational Trial in Q4 2025

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Oct 8, 2025, 7:30 AM EDT - 7 months ago

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

Aug 11, 2025, 4:10 PM EDT - 9 months ago

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

Neurogene Announces Registrational Trial Design for Emboldenâ„¢ Study of NGN-401 Gene Therapy for Rett Syndrome

Jun 30, 2025, 4:01 PM EDT - 11 months ago

Neurogene Announces Registrational Trial Design for Emboldenâ„¢ Study of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

May 16, 2025, 7:00 AM EDT - 1 year ago

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

May 9, 2025, 7:30 AM EDT - 1 year ago

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

Apr 28, 2025, 5:00 PM EDT - 1 year ago

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACTâ„¢ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Apr 2, 2025, 4:01 PM EDT - 1 year ago

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACTâ„¢ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Mar 24, 2025, 4:10 PM EDT - 1 year ago

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Neurogene Transcript: Virtual CNS Forum

Mar 19, 2025, 9:30 AM EDT - 1 year ago

Neurogene Transcript: Virtual CNS Forum

Neurogene Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 1:00 PM EDT - 1 year ago

Neurogene Transcript: Leerink Global Healthcare Conference 2025

Neurogene Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 9:50 AM EST - 1 year ago

Neurogene Transcript: TD Cowen 45th Annual Healthcare Conference

Neurogene to Participate in Upcoming Conferences

Feb 24, 2025, 7:30 AM EST - 1 year ago

Neurogene to Participate in Upcoming Conferences

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Nov 18, 2024, 5:25 PM EST - 1 year ago

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 18, 2024, 6:45 AM EST - 1 year ago

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Transcript: Study Update

Nov 11, 2024, 4:30 PM EST - 1 year ago

Neurogene Transcript: Study Update

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Nov 11, 2024, 4:01 PM EST - 1 year ago

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

d_risk
d_risk May. 12 at 8:33 PM
$NGNE - Neurogene Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +264.9% above peer average (42,757 vs 11,717 across 653 peers). NGNE’s 10‑Q adds sharper warnings on NGN‑401’s safety after a fatal AAV event, expanded clinical/regulatory uncertainty (incl. foreign trials, expedited and orphan/RPD designations offering no guarantees), heavier financing and single‑asset dependence, concentration and weather risk at its Houston plant, greater IP/licensing and litigation exposure, tighter global pricing/reimbursement and China/AML compliance risks, CVR/merger overhead, and newly flagged internal‑control weaknesses as a recent SPAC‑style reverse‑merger public company. 🟢 Added 🟠 Removed https://d-risk.ai/NGNE/10-Q/2026-05-12
0 · Reply
Buerll
Buerll May. 12 at 12:24 PM
$NGNE https://www.stocktitan.net/news/NGNE/neurogene-highlights-data-at-asgct-meeting-supporting-therapeutic-ek25bd65edsu.html
0 · Reply
King_of_Bio
King_of_Bio May. 6 at 7:23 PM
$NGNE Looking famn good
0 · Reply
lukasgx
lukasgx May. 6 at 2:42 PM
$NGNE hitting new high in few weeks
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 29 at 11:20 PM
$NGNE Current Stock Price: $26.44 Contracts to trade: $25.0 NGNE May 15 2026 Call Entry: $1.50 Exit: $2.00 ROI: 34% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Buerll
Buerll Apr. 28 at 1:22 PM
$NGNE https://m.in.investing.com/news/stock-market-news/guggenheim-reiterates-neurogene-stock-rating-with-69-target-93CH-5362097?ampMode=1
0 · Reply
laaarsas
laaarsas Apr. 27 at 6:20 PM
$NGNE So what data is expected here in the summer?
0 · Reply
lukasgx
lukasgx Apr. 27 at 3:29 PM
$NGNE climbing over 40+++
1 · Reply
focafoca99
focafoca99 Apr. 20 at 1:39 PM
$NGNE appointed Christy Shafer as chief commercial officer and added Christine Mikail to its board.
0 · Reply
Gogobisous
Gogobisous Apr. 20 at 12:21 PM
$NGNE looks like they might be gearing up for not only for commercialization but a strategic transaction. https://ir.neurogene.com/news-releases/news-release-details/neurogene-appoints-christy-shafer-chief-commercial-officer-and
0 · Reply
stockanalysis_
stockanalysis_ Apr. 19 at 12:24 AM
$AREB $SNSE $CAR $NGNE $AZI
0 · Reply
Buerll
Buerll Apr. 17 at 5:20 PM
$NGNE Thanks for the dip. Just started a position here.
0 · Reply
BiotechButterflies
BiotechButterflies Apr. 17 at 2:32 PM
$NGNE rally before the mid-26 interim data expected... should be an exciting dataset - I'm betting on a successful one...
1 · Reply
lukasgx
lukasgx Apr. 16 at 10:56 PM
$NGNE Dont say I didn’t advise…..
0 · Reply
TheSealeGroup
TheSealeGroup Apr. 16 at 7:08 PM
$NGNE this is some weird action over the past two days. I’m interested in what it means for the future.
0 · Reply
BenGang
BenGang Apr. 16 at 12:04 AM
$TNGX $NGNE $HIMS
0 · Reply
Johnny_443
Johnny_443 Apr. 15 at 6:12 PM
$TSHA $NGNE both are actually significantly up today...
0 · Reply
stockanalysis_
stockanalysis_ Apr. 11 at 7:44 PM
Most Shorted Stocks: $AREB $SNSE $CAR $NGNE $AZI Download this screener: https://stockanalysis.com/list/most-shorted-stocks/?ref=saveontrading
0 · Reply
focafoca99
focafoca99 Apr. 8 at 10:24 PM
$NGNE granted inducement stock options covering 69,140 shares to four new employees.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 6:25 PM
$NGNE RSI: 45.04, MACD: 0.0816 Vol: 1.39, MA20: 21.08, MA50: 19.73 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RetireB4FortyX
RetireB4FortyX Mar. 31 at 2:30 AM
$SNSE $NGNE $KALV $XWEL Most Shorted Stocks This Week of 3/30/2026 Full Stock Analysis Here: https://shorturl.at/33ujH Make sure to follow and sign up for our free newsletter. We will be rolling out our new discord this week
0 · Reply
Quantumup
Quantumup Mar. 25 at 7:37 PM
Cantor reiterated $TSHA Overweight; $19 $NGNE $ACAD Here's what Cantor said: https://x.com/Quantumup1/status/2036889409476571613?s=20
0 · Reply